Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy and Safety of Sirolimus for Treating Lymphangioleiomyomatosis (LAM)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by Office of Rare Diseases (ORD).
Recruitment status was  Active, not recruiting
FDA Office of Orphan Products Development
Information provided by:
Office of Rare Diseases (ORD) Identifier:
First received: December 20, 2006
Last updated: August 27, 2009
Last verified: August 2009